Table 3.
Pathway profiles using GeneGo Pathway Maps analysis.
| Pathways | P-value | Count* |
|---|---|---|
| Development_Role of CDK5 in neuronal development | 2.68E-11 | 12/34 |
| Development_Gastrin in cell growth and proliferation | 3.86E-11 | 15/62 |
| Immune response_Gastrin in inflammatory response | 2.00E-10 | 15/69 |
| Signal transduction_Activation of PKC via G-Protein coupled receptor | 5.21E-10 | 13/52 |
| Cytoskeleton remodeling_Cytoskeleton remodeling | 9.88E-10 | 17/102 |
| Glycolysis and gluconeogenesis (short map) | 1.43E-09 | 14/67 |
| Cytoskeleton remodeling_Neurofilaments | 7.28E-09 | 9/25 |
| Transcription_Role of Akt in hypoxia induced HIF1 activation | 1.59E-08 | 9/27 |
| Immune response_MIF - the neuroendocrine-macrophage connector | 1.93E-08 | 11/46 |
| Development_Prolactin receptor signaling | 2.50E-08 | 12/58 |
| Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling | 2.72E-08 | 16/111 |
| Development_Gastrin in differentiation of the gastric mucosa | 3.22E-08 | 10/38 |
| Development_GM-CSF signaling | 4.94E-08 | 11/50 |
| Development_EGFR signaling pathway | 6.66E-08 | 12/63 |
| Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho GTPases | 7.06E-08 | 8/23 |
| G-protein signaling_Proinsulin C-peptide signaling | 7.62E-08 | 11/52 |
| Development_Glucocorticoid receptor signaling | 1.04E-07 | 8/24 |
| Development_VEGF signaling and activation | 1.16E-07 | 10/43 |
| Cell adhesion_Histamine H1 receptor signaling in the interruption of cell barrier integrity | 1.85E-07 | 10/45 |
| Immune response_Inhibitory action of Lipoxins on pro-inflammatory TNF-alpha signaling | 1.85E-07 | 10/45 |
| Signal transduction_Calcium signaling | 1.85E-07 | 10/45 |
| Regulation of CFTR activity (norm and CF) | 2.50E-07 | 11/58 |
| Translation _Regulation of translation initiation | 2.92E-07 | 8/27 |
| Immune response_Histamine H1 receptor signaling in immune response | 3.53E-07 | 10/48 |
| Immune response_IL-2 activation and signaling pathway | 4.34E-07 | 10/49 |
| Transcription_P53 signaling pathway | 5.48E-07 | 9/39 |
| Development_Slit-Robo signaling | 7.19E-07 | 8/30 |
| Development_Ligand-dependent activation of the ESR1/AP-1 pathway | 7.81E-07 | 6/14 |
| Development_PDGF signaling via STATs and NF-kB | 1.24E-06 | 8/32 |
| Signal transduction_AKT signaling | 1.33E-06 | 9/43 |
| Development_VEGF signaling via VEGFR2 - generic cascades | 2.00E-06 | 9/45 |
| Development_Thrombopoietin-regulated cell processes | 2.00E-06 | 9/45 |
| Mucin expression in CF via IL-6, IL-17 signaling pathways | 2.04E-06 | 8/34 |
| Development_TGF-beta-dependent induction of EMT via RhoA, PI3K and ILK. | 2.43E-06 | 9/46 |
| Development_PIP3 signaling in cardiac myocytes | 2.93E-06 | 9/47 |
| Cytoskeleton remodeling_Keratin filaments | 3.24E-06 | 8/36 |
| Development_Thyroliberin signaling | 3.61E-06 | 10/61 |
| Development_A3 receptor signaling | 4.22E-06 | 9/49 |
| Transport_RAN regulation pathway | 4.42E-06 | 6/18 |
| Immune response_IL-7 signaling in T lymphocytes | 5.01E-06 | 8/38 |
| Muscle contraction_Regulation of eNOS activity in endothelial cells | 5.66E-06 | 10/64 |
| Immune response_IL-6 signaling pathway | 7.57E-06 | 7/29 |
*Number of known O-GlcNAcylated proteins over the total number of proteins annotated in the corresponding GeneGO pathways. The table is ranked based on the pathway enrichment P-values.